Brinda Balakrishnan/LinkedIn
Dec 22, 2025, 12:39
Shining a Light on von Willebrand Disease: An Often Overlooked Bleeding Disorder
Brinda Balakrishnan, Board Member of Aurinia Pharmaceuticals Inc., shared a post by Star Therapeutics on LinkedIn:
“There continue to be many sizable, rare disorders with few to no therapeutic options. Glad that Star is shining a light on VWD and developing novel medicines to address patient needs!”
Quoting Star Therapeutics‘ post:
“von Willebrand Disease is often overlooked compared to other bleeding disorders like hemophilia, leaving many patients without the resources and support they deserve.
Listen as Nick shares his experience growing up with a condition that was frequently misunderstood and the impact that has had on his journey with VWD.”
Find more related posts on Hemostasis Today.
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link
-
Jan 12, 2026, 01:07Akshat Jain Presents The New Edition of Global Sickle Cell Disease Insight Publication
-
Jan 11, 2026, 21:05Simona Sacco Shares Expert Guidance for Clinicians on Minor Ischemic Stroke
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates